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1ABSTRACT
The therapeutic effects of MSCs-based IGF-1/EGFP dual gene 
by sorting system in rat myocardial infarction model 
Subin Jung
Dept. of Science for aging
The Graduate School, Yonsei University
(Directed by Professor Donghoon Choi)
Myocardial infarction (MI) is the most important disease of the cardiovascular diseases 
because it causes cardiomyocyte death, scar formation, wall thinning and collagen 
degradation via blockage of the coronary arteries. Mesenchymal stem cells (MSCs)-based 
gene therapy has attracted attention due to their unique therapeutic properties such as 
capacity of multipotent differentiation into variety of cell types, immunomodulation, and 
paracrine effects. Furthermore, Insulin-like growth factor-1 (IGF-1) has substantially 
beneficial effects on cardiomyocyte function including cell proliferation and survival. In 
the present study, a simplified method have been established the MSCs-based IGF-
1/EGFP gene therapy using the selection plasmid vector with sorting system.
To improve the transfection efficiency of MSCs using non-viral carriers, the selection 
vector was constructed by inserting IGF-1 coding sequences as a target gene into 
2pEF1/His C vector, and sequentially cloned enhanced green fluorescent protein (EGFP) 
as a selection marker gene with its CMV promoter. By using the selection vector 
(pEF1/His C::IGF-1::EGFP), both IGF-1 and EGFP genes were expressed in MSCs in 
vitro. Dual-genes expressing MSCs were collected solely via fluorescence activated cell 
sorter (FACS) system and the purity was approximately 95.1%. 
To investigate the therapeutic effects by sorted pEF1/His C::IGF-1::EGFP-MSCs, rat 
MI models were divided into 4 groups; PBS, control MSCs, unsorting MSCs and sorting 
MSCs. After 2 weeks after MSCs transplantation, the MI hearts were harvested. The 
green fluorescence as transfected MSCs was visualized in myocardium of ischemic left 
ventricle and observed in both unsorting and sorting groups. Interestingly, the IGF-1 
transfected MSCs were significantly localized in sorting groups compared to unsorting 
groups. Also, the expression of IGF-1 was increased in sorting groups. 
The TTC staining and the Masson’s trichrome staining were proceeded to evaluate the 
therapeutic effects of dual gene system with FACS through histological assessment. The 
infarct size by TTC staining was significantly decreased in sorting groups compared to 
other groups (sorting 5.74% vs. PBS 31.50%, Intact MSCs 12.61%, unsorting 10.42%). 
The fibrosis area of myocardium layer relatively decreased in sorting group compared to 
other groups.
The present study demonstrated that the expression of IGF-1 can attenuate the fibrosis 
and reduce the infarct size in rat MI models. Also, the selection plasmid vector with 
sorting system efficiently enhanced therapeutic effects in MSCs-based gene therapy. 
Furthermore, this selection plasmid vector together with sorting system could be a 
practical application in a wide range of diseases. Also, it could be used in cell-based gene 
therapy as a treatment tool, by simply replacing the gene of interest or based cell source.
Key words: insulin-like growth factor (IGF-1), selection plasmid vector, dual promoters, 
sorting system, transduced gene effect, myocardial infarction (MI)
3I. INTRODUCTION
Cardiovascular diseases (CVDs) are the heart or blood vessel diseases such as 
myocardial infarction, hypertensive heart disease, cardiomyopathy, atrial fibrillation, 
peripheral artery disease and venous thrombosis. Furthermore, CVDs are the leading 
cause of death throughout the world [1,2,3]. One of the important CVDs is myocardial 
infarction (MI) because it causes cardiomyocyte death, scar formation, wall thinning and 
collagen degradation via blockage of the coronary arteries [4,5]. Therefore, therapeutic 
strategies are essential to repair the damaged cardiac function and prevent the destructive 
ventricular remodeling after MI.
Many clinicians and researchers have been trying to treat MI such as balloon 
angiography and stent, bypass surgery, heart transplantation, and artificial heart surgeries 
[6,7,8,9]. However, the current treatments for MI still remain the problems to be solved as 
follows; myocardial salvage is incomplete due to restenosis and a very high cost. 
Furthermore, heart transplantations are interrupted by shortage of donor organs [8,9]. 
Recently, the stem cell-based therapies have been suggested as a promising approach for 
people suffering a MI [8].
For restoration of damaged cardiac after MI, prior investigators have attempted cells 
transplantation into the injured myocardium to repair of cardiac function. A variety of cell 
types was used to restore damage heart as follow; cardiomyocyte progenitor cells, 
hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), cardiac stem cells 
(CSCs), embryonic stem cells (ESCs), skeletal myoblast, fetal and umbilical cord blood 
cells [8,10]. 
MSCs are free of ethical concerns and can be easily obtained from the patient [11]. 
That is why MSCs are the best cell type as a source for transplantation into MI heart. 
4Moreover, MSCs have many advantages such as ease of isolation, capacity of multipotent 
differentiation into variety of cell types, immunomodulation, and paracrine effects 
[9,11,12]. However, MSCs-based cell therapy has limitation as a new treatment for 
patients with various diseases because of their low transplantation and poor cell viability 
[12]. Hence, many studies have been tried to overcome the limitation and enhance the 
therapeutic effects of MSCs-based cell therapy, including gene transfection [13]. 
MSCs-based gene therapy has developed the strategies of cell treatment via viral 
carrier or non-viral carrier. However, the therapeutic effects of transfected MSCs are 
reported to be low. The reason is that MSCs have low transfection efficiency using non-
viral carrier [13,14]. Originally, gene delivery systems can be divided into two strategies: 
viral carrier and non-viral carrier [14]. The viral carrier systems including retrovirus, 
lentivirus, and adenovirus are high efficient in gene transfection (also called infection). 
However, the viral carrier systems still remain disadvantages such as insertional 
mutagenesis and immunogenicity, and pathogenic risk for clinical trials. On the other 
hand, non-viral carriers are efficient delivery systems due to their safety, stability, easy 
manufacturing, and low immunogenicity. But, the disadvantage of non-viral carrier 
systems is relatively low transfection efficiency compared to viral infection, 
approximately 20~25% [14,15,16]. Therefore, the low transfection efficiency of non-viral 
carrier systems is the most critical for clinical trials. 
Insulin-like growth factor-1 (IGF-1) is similar to structure of insulin hormone and also 
called somatomedin C [17]. The IGF-1 is secreted by almost all tissues and plays an 
important role in cell growth, differentiation, and transformation [18,19]. In the heart, 
IGF-1 has substantial beneficial effects on cardiomyocyte function including proliferation 
and survival [18]. According to Davis et. al., IGF-1 deficiency in IGF-1 knockout mice 
leads to an impaired cardiac remodeling and increases apoptosis in myocardial infarction. 
While overexpression of IGF-1 prevents cell death of myocardium, attenuates ventricular 
dilatation and wall stress in infarcted heart [18]. Researchers have noticed that IGF-1 
administration would be promising method to prevent ischemia-reperfusion injury. 
5Methods of IGF-1 administration are classified into two categories; gene and protein 
delivery. Injection of recombinant protein is a simple method, but it has limitations 
involving expensive price or short half-lives of the protein to delivery an adequate 
amount of the protein. Whereas gene transfer therapy, especially using non-viral gene 
transfer, is inexpensive and has low cytotoxicity compared to viral gene transfer method 
[20]. Also, the angiogenic factors including IGF-1, vascular endothelial growth factor 
(VEGF), and transforming growth factor-beta (TGF-beta) were significantly increased 
after IGF-1 treatment in MI animal models. Furthermore, previous investigators 
demonstrated that IGF-1 induced the activation of resident cardiac stem cells and 
increased engraftment and survival of several cell types including MSCs, embryonic stem 
cells and smooth muscle cells [18].
To improve the therapeutic effect of MI, selection vector system containing dual gene 
was constructed by enhanced green fluorescent protein (EGFP) as a selective marker and 
IGF-1 as a gene of interest. The dual promoter vectors were used for blocking of fusion 
proteins. The aim of this study is the verification of therapeutic effects via MSCs-based 
gene (IGF-1) therapy using FACS sorting system in rat MI models.
6II. MATERIALS AND METHODS
2.1. Animals 
Spraque-Dawley (SD) rats from ORIENT BIO (Seongnam, Korea) were cared for 
according to the Association for Assessment and Accreditation of Laboratory Animal 
Care International system. All animal experiments confirmed to the International Guide 
for the Care and Use of Laboratory Animals. All experimental procedures were examined 
and approved by the Animal Research Committee of Yonsei University College of 
Medicine.
2.2. Construction of selection vector - pEF1/His C::IGF-1 & pEF1/His C::IGF-
1::EGFP
pEF1/His C::IGF-1::EGFP selection vector was constructed by inserting rat IGF-1 
cDNA and EGFP DNA into pEF1/His C vector. pEF1/His C vector (invitrogen) are 6.2kb 
size designed for overexpression of recombinant proteins in mammalian cell lines. This 
construction of vector was divided into two steps; first step was rat IGF-1 cDNA was 
inserted into pEF1/His C vector (pEF1/His C::IGF-1 vector). And second step was EGFP 
DNA inserted into pEF1/His C::IGF-1 vector (pEF1/His C::IGF-1::EGFP vector). 
Rat IGF-1 cDNA was amplified by PCR with DNA polymerase (TaKaRa) using MSCs
cDNA as a template. The forward and reverse primers for IGF-1 were tagged EcoRI 
sequence and XbaI sequence, respectively. (Table 1). The PCR cycling conditions were 
95℃ for 5min, 32 cycles of 95℃ for 1min, 65℃ for 1min 30sec, 72℃ for 40sec and 
72℃ for 10min for final extension.
The amplified IGF-1 PCR products were loaded in 0.8% agarose gel and run. Then, IGF-
1 fragments were eluted with gel extraction kit (LaboPass), and the IGF-1 elution and 
7pEF1/His C vector was digested with restriction enzymes EcoRI (1830) and XbaI (1869), 
respectively. After enzyme cleavage, IGF-1 and vector fragments were purified and 
concentrated by using clean-up spin column (LaboPass). To fusion with IGF-1 and 
pEF1/His C vector fragments, DNA ligation reaction was conducted at 16℃ overnight 
incubation using T4 ligase (NEW ENGLAND BioLabs). Ligation products were 
transformed into DH5α competent cells. Transformed colony was screened by colony 
PCR to confirm whether they have an insert of interest. And this chosen cloning vector 
was confirmed by digesting PstI sites and verified through sequencing via 
Cosmogenetech. pEF1/His C::IGF-1 vector was constructed by this step.
Next step was sub-cloning by inserting EGFP DNA into pEF1/His C::IGF-1 vector. It was 
too large to insert EGFP DNA (1.6kb) into pEF1/His C::IGF-1 vector (6.6kb), so 
pEF1/His C::IGF-1 vector was reduced by cutting in restriction enzyme PvuII sites (2152, 
3248, 4317). EGFP DNA was isolated from pEGFP-C1 vector by cutting the site of 
restriction enzyme AseI (7) and MluI (1641). And then, Pfu DNA polymerase (ELPIS) 
has been used to make sticky ends into blunt ends with filling in step at 72℃ for 30min. 
Shortly after DNA precipitation step was processed. DNA ligation was conducted at 16℃
overnight incubation. This final cloning IGF-1/EGFP vector was confirmed by digesting 
EcoRI and NdeI restriction enzyme sites and examined through sequencing.
2.3. MSCs isolation, culture, and characterization
MSCs were isolated from four-week-old male Sprague Dawley rats (100±5g) by 
flushing the femurs and tibias with low glucose-Dulbecco’s modified Eagle’s medium 
(DMEM) (Welgene) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% 
penicillin/streptomycin solution (Gibco), using a 19-gauge needle. Flushing media were 
centrifuged at 1,600rpm for 5 minutes and suspended in complete medium. And then, 
suspension cells media were loaded onto a Ficoll-Paque (GE Healthcare Life Sciences). 
After being centrifuged at 1,600rapm for 30min, the following three layers (top, middle, 
and bottom) were visible. Transferred middle layer (mononuclear bone marrow cells) in 
8new 15ml conical tube and washed twice with PBS. This mononuclear bone marrow cells 
were seeded onto 100mm culture dishes. After 72hrs incubation, non-adherent cells were 
discarded, and the adherent cells were thoroughly washed twice with PBS and changed 
fresh MSCs media. This washing step was repeated every 2 days for 1 week. 
Characterization of MSCs was identified by presence of cell surface marker through Flow 
cytometry. Suspended single cells in FACS buffer (1X106 cells/100ul) were stained at 4℃
for 1hr with surface marker antibodies such as CD29-FITC (Biolegend), CD54-PE 
(Biolegend), CD90-FITC (Biolegend), CD45-PE (Biolegend), CD49d-FITC (Biolegend) 
according to the manufacturer’s instructions. After 1hr, cells were washed twice with PBS 
and resuspended in 300ul PBS. Fluorescent intensities of MSCs stained by antibodies 
were detected by BD FACSVerseTM flow cytometry. Data of each sample were detected 
by FITC (488nm) and PE (561nm) fluorescent parameters. Also, compensation step was 
proceeded to prevent for overlapping signals between two fluorescence dyes. Data 
analysis was performed by using BD FACSuiteTM software.
2.4. in vivo transfection using non-viral carrier and pEF1/His C::IGF-1::EGFP 
vector in MSCs (complexes of pEF1/His C::IGF-1::EGFP + PAM-ABP)
To confirm optimal time and concentration of transfection, the MSCs were plated at a 
density of 2x105 cells in 60mm culture dishes for 48hrs. MSCs were transfected with non-
viral carrier PAM-ABP and selection vector complexes at serial amount of pEF1/His 
C::IGF-1::EGFP ranging from 0 µg to 16 µg (0 µg, 0.5 µg, 1 µg, 2 µg, 4 µg, 8 µg and 16 
µg). Complexes of plasmid DNA and PAM-ABP were mixed by weight ratio of 1:5, and 
conjugated in 100µl PBS at room temperature (RT) for 30 minutes. Also, MSCs medium 
was exchanged with serum free DMEM for starvation during complex conjugation time. 
And then, PAM-ABP and selection vector complexes were treated in the MSCs. After 
4hrs of transfection, MSCs were washed with PBS and replaced with fresh complete 
medium. Continuously, transfected MSCs were incubated in 37℃ incubator for 24hrs or 
48hrs. After that time, the transfected cells were confirmed by fluorescent microscope for 
9detection of enhanced green fluorescent protein (EGFP). The conditioned medium was 
collected at 24hrs or 48hrs after transfection and measured the level of IGF-1 protein 
secreted by transfected MSCs using an ELISA kit (R&D Systems). Also, transfected 
MSCs were harvested using RNeasy mini kit (QIAGEN) for extraction of RNA. 
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
pEF1/His C::IGF-1 or pEF1/His C::IGF-1::EGFP transfected cells were harvested 
24hrs or 48hrs after transfection and total RNA was extracted by using RNeasy mini kit 
(QIAGEN). cDNA was synthesized by using Promega RT reagents (Promega) according 
to manufacturer’s protocol. Briefly, RNA with oligo(dt) primer and Nuclease-free water 
was preheated for 5min at 70℃, and immediately chilled in 4℃ for at least 5min. 
Reverse transcription reaction mix (nuclease-free water, ImProm-II™ 5X Reaction Buffer, 
MgCl2, dNTP Mix, Recombinant RNasin® Ribonuclease Inhibitor , ImProm-II™ 
Reverse Transcriptase) was added to RNA and primer mix for final reaction volume of 
20µl per tube. This mix was annealed at 25℃ for 5min, extended at 42℃ for 1hr, 
inactivated reverse transcriptase at 70℃ for 15min.
RT-PCR was processed with amfiEco kit (GenDEPOT). Primer sequences of rat IGF-1 
and rat GAPDH were listed on Table 1. The PCR cycling conditions of rat IGF-1 were 
95℃ for 5min, 28 cycles of 95℃ for 1min, 65℃ for 1min 30sec, 72℃ for 40sec and 
72℃ for 10min for final extension. And GAPDH PCR conditions were 95℃ for 5min,
28 cycles of 95℃ for 1min, 60℃ for 1min, 72℃ for 40sec and 72℃ for 10min for 
final extension. PCR products were loaded in 1.2% agarose gel containing red-safe 
(Intron).
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Table 1. Sequences of primers for RT-PCR
Forward Reverse
IGF-1 5’-TTT GAA TTC ATG GGG AAA ATC 
AGC AGT CT-3’
* GAATTC : EcoRI sequence
5’-TTT CTA GAC TGC ACT TCC TCT 
ACT TGT GTT C-3’
* TCTAGA : XbaI sequence
EGFP 5’-GTA GGT GTC ATT CTA TTC TGG 
GG-3’
5’-AAC CGT ATT ACC GCC TTT GA-3’
GAPDH 5’-AAT GCA TCC TGC ACC ACC AAC 
TGC-3’
5’-GGA GGC CAT GTA GGC CAT GAG 
GTC-3’
IGF-1: Insulin-like growth factor-1; EGFP: Enhanced green fluorescent protein; 
GAPDH: Glyceraldehyde 3-phophate dehydrogenase
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2.6. Enzyme-linked immunosorbent assay (ELISA)
The conditioned medium of transfected MSCs was collected by after 24hrs or 48hrs 
after incubation. Total 3ml of conditioned medium was harvested and was centrifuged at 
1600rpm for 3min. Supernatant was transferred to new 1.5ml eppendorf tube and the 
medium was measured by using rat IGF-1 enzyme-linked immunosorbent assay (ELISA) 
kit (R&D Systems) following the manufacturer’s instruction. Serum-free low glucose 
DMEM was used as a negative control. All controls and samples were assayed in 
triplicate and optical density was measured at 450nm.
2.7. Fluorescence-activated cell sorting (FACS)
Fluorescence-activated cell sorting (FACS) was processed to selection of only 
transfected MSCs using BD FACSAriaTM III (BD Biosciences). 24hrs after transfection, 
transfected MSCs were harvested and washed with FACS buffer once. And then, MSCs 
were suspended in 1ml FACS buffer, entrusted FACS specialist with samples. Transfected 
MSCs with pEF1/His C::IGF-1::EGFP was visualized as green fluorescence and selected 
by FITC filter (488nm). Data were analyzed by BD FACSDivaTM software (BD 
Biosciences).
2.8. Preparation of rat myocardial infarction (MI) model
Experimental myocardial infarction was induced at an age of 8 weeks to 9 weeks male 
Sprague-Dawley rats (270±10 g) as described previously. Rats were anesthetized by 
intraperitoneal injection of Zoletil (30mg/kg) and Rompun (10mg/kg). The anesthetized 
rats were ventilated with positive pressure (180ml/min) using Ventilator (Harvard 
Apparatus). And then, the rat heart was exposed through 2cm incision at the left lateral 
costal rib. The left anterior decending (LAD) was ligated with 6-0 prolene (ETHICON) 
beneath the left atrium for 30 minutes. After occlusion, the ligation was considered 
successful when color of left ventricle region became pale. After that time, followed by 
reperfusion and immediately proceeded with intramyocardial injection of cells or PBS. 
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100 µl of PBS or control MSC (1X106 cells in 100 µl PBS) or unsorting_pEF1/His 
C::IGF-1::EGFP-MSCs (1X106 cells in 100 µl PBS) or sorting_pEF1/His C::IGF-
1::EGFP- MSCs (1X106 cells in 100 µl PBS) were injected into 3-4 different sites of 
border zone using 31-gauge insulin needle (Becton, Dickinson and Company).
Animal groups were divided into four groups: PBS injection (LAD ligation and 
reperfusion, n=9), control MSCs (LAD ligation and reperfusion, 1.0X106 cells, n=8), 
unsorting_pEF1/His C::IGF-1::EGFP-MSCs (LAD ligation and reperfusion, 1.0X106
cells, n=8), sorting_pEF1/His C::IGF-1::EGFP- MSCs (LAD ligation and reperfusion, 
1.0X106 cells, n=8). 2 weeks after transplantation, the animals were re-anesthetized and 
sacrificed for MSCs localization and histological study, respectively.
2.9. MSCs localization in injection sites
To analyze MSCs engraftment (or localization) within infarcted myocardium following 
experimentally induced rat myocardial infarction, MSCs treated animals were sacrificed 2 
weeks after transplantation. The heart of rat was perfused with PBS and fixed in 10% 
formalin solution overnight. And next day, heart tissue was embedded in OCT compound 
(SAKURA) and frozen with dry ice, and sectioned transversally with cryostat. 
Cryosections were mounted with mounting solution containing 4′,6-diamidino-2-
phenylindole (DAPI) (Santa cruz Biotechnology, Inc) and covered with cover slide. 
Mounted sections were examined under confocal fluorescent microscope, and DAPI and 
EGFP were detected in heart sections.
2.10. Immunofluorescence (IF)
To confirm that IGF-1 expression from MSCs transfected with pEF1/His C::IGF-
1::EGFP in ischemic heart. MSCs treated animals were sacrificed 2 weeks after 
transplantation. The heart of rat was perfused with PBS and fixed in 10% formalin 
solution overnight. And next day, heart tissue was embedded in OCT compound 
(SAKURA) and frozen with dry ice, and sectioned transversally with cryostat. 
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Cryosections were washed PBS containing Triton X-100 (Sigma). And sections were 
permeabilized with mix of 100% methanol and 30% H2O2. Then, washed 3 times with 
PBS and incubated with 3% BSA (blocking step). Next, cryosections were incubated with 
primary antibody (IGF-1 antibody, Santa cruz Biotechnology, Inc, 1:50) in blocking 
solution at RT for 2hr. and then, the sections were washed with PBS three times and 
incubated with secondary antibody (Cy5.5 Donkey anti-goat antibody, Biolegend, 1:200)
at RT for 1hr. Sections were washed with PBS, mounted with mounting solution 
containing 4′,6-diamidino-2-phenylindole (DAPI) (Santa cruz Biotechnology, Inc) and 
covered with cover slide. Sections were examined under Olympus fluorescence 
microscope, and DAPI and Cy5.5 were detected in heart sections.
2.11. 2,3,5-Triphenyltetrazolium chloride (TTC) staining
Myocardial infarct size was measured by using TTC (Sigma-Aldrich) staining. PBS or 
MSCs (control or unsorting or sorting) treated animals were sacrificed 2 weeks after 
implantation. Heart was perfused with PBS and incubated in 1% TTC for 15 minutes at 
37℃ water bath. And then, heart tissue were fixed in 10% formalin at 4℃ for overnight. 
This heart was sectioned transversally and photographed with a digital camera. The 
infarct size was measured by calculating the ratio of cumulative infarcted area to the 
entire left ventricle. Analysis of the infarcted area was performed using Image J software 
program.
2.12. Trichrome staining
Heart was perfused with PBS and fixed in 10% formalin solution. Heart sections were 
stained with Trichrome stains (Masson) kit (Sigma-Aldrich) according to the 
manufacturer’s recommendations. In briefly, the cryosection slides were stained with 
Bouin’s solution at 56℃ for 15min and washed in running tap water until yellow color 
from sections was disappeared. And then, the slides were stained with Weigert’s iron 
hematoxylin solution for 15min and washed under tap water for 5min. And the sections 
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were stained with Blebrich scarlet-acid fucshin solution for 5min and rinsed in deionized 
water. Next, the sections were placed in working Phosphotungstic/Phosphomolybdic acid 
solution for 5min and Anilline blue solution for 5min. the sections were treated with 1% 
acetic acid for 2min and rinsed deionized water. The sections were dehydrated through 
from 70% alcohol to 100% alcohol, clear in xylene. And then, the sections were mounted 
using permount (Fisher Scientific).
2.13. Statistical analysis
Data are presented as mean ± standard deviation. The data was analyzed using T-test 
followed by Mann-Whitney test. A p-value less than 0.05 were considered to indicate 
statistical significance. All statistical analyses were performed using GraphPad Prism 5 
for Windows (version 5.01, GraphPad Software).
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III. RESULTS
3.1. Construction of selection plasmid vector expressing dual gene; IGF-1 and EGFP
pEF1/His C::IGF-1::EGFP selection vector was constructed by inserting rat IGF-1 
cDNA and EGFP DNA into pEF1/His C vector. The construction was divided into 
pEF1/His C::IGF-1 vector and pEF1/His C::IGF-1::EGFP vector, respectively (Figure 1, 
2). In the first step of cloning, pEF1/His C::IGF-1 was intermediated products of cloning 
selection vector that made by inserting rat IGF-1 cDNA into pEF1/His C vector (Figure 
1A). Enzyme cutting with PstI site and sequencing were proceeded to confirm whether 
construction of cloned vector is correct. Figure 1B and 1C indicated that correct size of 
constructed vector after enzyme cutting, and the cloned vector was identified by a 100% 
in sequencing data (Figure 1). Size of final cloned vector pEF1/His C::IGF-1 was 6645bp 
(Figure 3A). To confirm the gene expression of constructed IGF-1 by human EF1 alpha 
promoter, pEF1/His C::IGF-1 was transfected in H9c2 cells which is a subclone of the 
original clonal cell line derived from embryonic BD1X rat heart tissue, and the IGF-1 
expression was identified by RT-PCR. Levels of IGF-1 expression were increased in 
dose-dependent manner (0 µg to 4 µg) (Figure 1D). 
Finally, EGFP gene was inserted into pEF1/His C::IGF-1 vector. To confirm the cloned 
vector, enzyme cutting using EcoRI and NdeI, and sequencing were processed (Figure 2).
pEF1/His C::IGF-1::EGFP vector was successfully constructed and the size of final 
cloned vector pEF1/His C::IGF-1::EGFP was 6121bp (Figure 3B).
16
Figure 1. Construction of pEF1/His C::IGF-1 and identification of cloned vector. (A) 
First step in construction of cloning vector; pEF1/His C::IGF-1. Enzyme cutting and 
sequencing analysis were processed to confirm whether construction of pEF1/His C::IGF-
1 vector is correct. (B) Agarose gel electrophoresis of digested products with PstI 
restriction enzyme. (C) Result of sequencing. (D) Agarose gel electrophoresis of RT-PCR 
for IGF-1. The band intensities were increased in dose-dependent manner at 0 μg to 4 μg.
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Figure 2. Construction of pEF1/His C::IGF-1::EGFP and identification of cloned 
vector. (A) Second step in construction of cloning vector; pEF1/His C::IGF-1::EGFP. 
Enzyme cutting and sequencing analysis were processed to confirm whether construction 
of pEF1/His C::IGF-1::EGFP vector is correct. (B) Agarose gel electrophoresis of 
digested products with EcoRI and NdeI restriction enzyme. (C) Result of sequencing.
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Figure 3. pEF1/His C::IGF-1 and pEF1/His C::IGF-1::EGFP selection vector maps.
Construction of pEF1/His C::IGF-1 and pEF1/His C::IGF-1::EGFP vector. (A) pEF1/His 
C::IGF-1 vector. Rat IGF-1 cDNA was inserted into pEF1/His C vector. (B) pEF1/His 
C::IGF-1::EGFP selection vector. CMV promoter and EGFP in pEGFP-C1 vector were 
inserted into pEF1/His C::IGF-1 vector. The constructed vector contains dual promoters 
and dual genes; human EF1 alpha promoter and IGF-1 gene, CMV promoter and EGFP 
gene. Further information was described in materials and methods.
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3.2. Characterization of bone marrow-derived mesenchymal stem cells (BM-MSCs)
Rat BM-MSCs were isolated by using the Ficoll-Plaque gradient centrifugation. The 
morphology of MSCs was typically observed such as spindle-shaped (Figure 4A). To 
characterize the phenotype of primary BM-MSCs, the cultured cells were stained with 
positive and negative cell surface markers, such as CD29-FITC, CD54-PE, CD90-FITC, 
CD45-PE, and CD49d-FITC; CD29, CD54 and CD90 were positive marker, CD45 and 
CD49d were negative marker of MSCs. The BM-MSCs were positive for MSCs markers 
such as CD29 (99.8%), CD54 (96.3%), and CD90 (99.7%). Also, MSCs were negative 
for CD45 (0.34%) and CD49d (0.42%) (Figure 4B). 
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Figure 4. Characterization of MSCs derived from rat bone marrow. (A) Morphology 
of primary cultured BM-MSCs showed spindle-shaped appearance. And cell adherence to 
cell culture plate. Magnification 40X. (B) Expression of surface markers in isolated 
MSCs. Histogram showed the relative staining intensity of MSCs by flow cytometry for 
CD29-FITC, CD54-PE, CD90-FITC, CD45-PE, and CD49d-FITC. The red histograms 
represent staining with respective surface marker antibody, whereas the black histograms 
mean staining with isotype controls. 
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3.3. The transfection efficiency of pEF1/His C::IGF-1::EGFP in rat BM-MSCs
To determine the transfection dose of pEF1/His C::IGF-1::EGFP in rat BM-MSCs, 
final selection vector was transfected in a dose-dependent (from 0 μg to 16 μg) manner. 
RT-PCR, ELISA and fluorescence microscopy were performed in time-dependent (24hr 
and 48hr) after transfection. The EGFP expressions by fluorescence microscope were 
dose-dependently visualized from 1 μg and maximized at 8 μg dose in both 24hr and 48hr 
(Figure 5). Also, the IGF-1 mRNA expressions were dose-dependently increased and 
maximized at 8 μg dose in RT-PCR (Figure 6A, B, C). 
To determine the levels of IGF-1 protein, ELISA was performed by the conditioned 
culture medium of transfected MSCs. Conditioned medium of pEF1/His C::IGF-1::EGFP 
transfected MSCs showed a significantly higher level of IGF-1 compared to negative 
control (0 μg) (Figure 6D). Levels of IGF-1 secretion were enhanced up to 8 μg, and then 
began to decline both 24hr and 48hr after transfection (Figure 6D). Furthermore, amount 
of IGF-1 secretion from transfected MSCs at 48hr post transfection is increased when 
compared to 24hr after transfection. Therefore, transfection efficiency of pEF1/His 
C::IGF-1::EGFP was achieved maximum at 8 μg dose.
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Figure 5. EGFP expression in MSCs serial-transfected with pEF1/His C::IGF-
1::EGFP using fluorescence microscopy. MSCs were successfully transfected with 
pEF1/His C::IGF-1::EGFP and non-viral carrier, as shown by green fluorescence. The 
expression of EGFP was analyzed by using phase contrast and fluorescence microscopy 
at serial amount of pEF1/His C::IGF-1::EGFP. EGFP expression was peaked at 8ug. 
Magnification 40X. A1 to G1: Bright field (24hr), A2 to G2: Bright field (48hr), H1 to 
N1: Fluorescence microscopy (24hr), H2 to N2: Fluorescence microscopy (48hr).
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Figure 6. Analysis of IGF-1 expression in mRNA and protein levels. pEF1/His 
C::IGF-1::EGFP and non-viral carrier were transfected into MSCs. After 24hr and 48hr, 
MSCs culture supernatant and cells were harvested for analysis of ELISA and RT-PCR, 
respectively. Agarose gel electrophoresis of RT-PCR for IGF-1 and GAPDH at 24hr (A) 
and 48hr (B).The band intensity (C) was quantified image J analysis. (D) ELISA. 24hr 
and 48hr after transfection, IGF-1 protein secreted by the transfected cells were measured 
by conditioned medium using ELISA. It was showed that IGF-1 expression was increased 
gradually in dose dependent manner and reached a maximum at 8ug. For the comparison 
between the two times (24hr and 48hr), levels of IGF-1 expression in 48hr were 2.6 fold 
higher than IGF-1 expression in 24hr.  
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3.4. Transfection efficiency evaluation by FACS in BM-MSCs
Transfection efficiency of MSCs with non-viral carrier PAM-ABP was evaluated by 
FACS. Transfection efficiency was estimated on the basis of the percentage of MSCs 
expressing EGFP via flow cytometric analysis. The transfection efficiency of pEF1/His 
C::IGF-1::EGFP and non-viral carrier PAM-ABP in MSCs was approximately 20% 
(Figure 7A). After sorting, the transfection efficiency was increased up to 95.1% by 
EGFP selection (Figure 7B). The purity of transfected MSCs was increased 
approximately 4.8 fold after sorting process.  
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Figure 7. Transfection efficiency of MSCs with pEF1/His C::IGF-1::EGFP and 
purity following FACS selection. A. Prior to FACS cell sorting. Transfection efficiency 
of MSCs with pEF1/His C::IGF-1::EGFP and non-viral carrier PAM-ABP was 
approximately 20% (P4). B. After FACS cell sorting. Transfected MSCs were collected 
following FACS and its purity was increased up to 95.1%. That is meaning of that almost 
all MSCs shows a green fluorescent signal (EGFP) and IGF-1. 
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3.5. Engraftment of pEF1/His C::IGF-1::EGFP transfected MSCs in ischemic heart
The MI rat models were divided four groups; MI-PBS, MI-control MSCs, MI-
unsorting MSCs and MI-sorting MSCs (Figure 8). Experimental design and schematic 
flow diagram were described in Figure 8.
The green fluorescence as pEF1/His C::IGF-1::EGFP transfected MSCs was visualized in 
both unsorting and sorting groups. The transfected MSCs were observed much more in 
MI-sorting groups compared to MI-unsorting groups (Figure 9). Furthermore, the 
pEF1/His C::IGF-1::EGFP transfected MSCs were localized in myocardium of ischemic 
left ventricle (Figure 9C, F).
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Figure 8. Experimental design and schematic flow diagram of in vivo application.
(A) The systematic flow diagrams of cell sorting for in vivo application. Myocardial
infarction models were divided into 4 groups; PBS, control MSCs, unsorting MSCs, and 
sorting MSCs. MSCs injected groups; control MSCs, unsorting, and sorting group were 
received same amount of cells (1X106 cells). (B) Experimental design for in vivo. 
Animals were sacrificed at 2 weeks after transplantation. And then MSC localization, 
immunofluorescence, TTC staining, and trichrome staining were processed.
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Figure 9. The localization of MSCs transfected with pEF1/His C::IGF-1::EGFP and 
non-viral carrier PAM-ABP in ischemic heart. The green fluorescence indicated EGFP 
distribution in ischemic left ventricle. Fluorescence imaging showed more green 
fluorescence in MI-sorting group compared to unsorting group. (A to C) unsorting group 
in ischemic heart; (D to F) sorting group in ischemic heart. Magnification 100X.
.
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3.6. Expression of IGF-1 in ischemic heart after transplantation of MSCs with 
pEF1/His C::IGF-1::EGFP
To investigate IGF-1 expression in MSCs transfected with pEF1/His C::IGF-1::EGFP, 
the red fluorescence as IGF-1 expression was detected in myocardium layer of both 
unsorting and sorting groups (Figure 10). The expression of IGF-1 was significantly 
increased in MI-sorting group compared with MI-unsorting group.
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Figure 10. Image for expression of IGF-1 in MSCs transfected with pEF1/His 
C::IGF-1::EGFP and non-viral carrier PAM-ABP in ischemic heart.
The expression of IGF-1 in BM-MSCs was observed in immunofluorescence staining. 
IGF-1 was significantly expressed in MI-sorting group compared to MI-unsorting group. 
IGF-1 is stained in red (Cy 5.5), Magnification 100X. (A to C) unsorting group in 
ischemic heart; (D to F) sorting group in ischemic heart.
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3.7. Improved myocardial repair in ischemic myocardium with pEF1/His C::IGF-
1::EGFP
To investigate the therapeutic effects by sorting system of IGF-1 transfected MSCs in 
myocardial infarction, TTC and Masson’s trichrome staining were performed. The infarct 
size was measured using Image J software program and the results are as follows: PBS 
31.50%, control MSCs 12.61%, unsorting MSCs 10.42% and sorting MSCs 5.74% 
(Figure 11B). The infarct size was significantly decreased in sorting group compared to 
PBS group (Figure 11A, B). Furthermore, the infarct size of sorting group was protected 
2 fold compared to unsorting group (sorting 5.74% vs. unsorting 10.42%, Figure 11).
Masson’s trichrome staining is used to distinguish collagen from muscle in heart. The 
density of stained myocardium layer in sorting group was lower than other groups (Figure 
11C).
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Figure 11. Analysis of histological evaluation. The infarcted hearts were stained by TTC 
staining (A) and Masson’s trichrome staining (C). The infarct area was quantified by 
image J analysis (B). *P < 0.05. The infarct size was significantly decreased in sorting 
group compared to other groups. In Masson’s trichrome staining, the fibrosis was lower 
than other groups. The hearts muscle were stained a red, whereas the collagen was stained 
blue. Magnification 200X.
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IV. DISCUSSION
The heart constantly beats to supply with oxygen and nutrients, like any muscle in the 
body. The cardiac ischemia or MI was commonly known as a heart attack. If one of 
arteries or branches in heart becomes blocked suddenly, a portion of the heart is starved 
of oxygen, a condition called cardiac ischemia [4,21]. The MI causes the death of a 
patient resulting in necrosis of cardiac cells. For that reason, MI was known a major cause 
of death worldwide [4,22]. The infarcted heart causes cardiomyocyte death, scar 
formation, wall thinning and collagen degradation [4,5]. Therefore, prior investigators 
have tried to repair the damaged cardiac function and prevent the destructive ventricular 
remodeling. Recently, new strategies have been suggested to overcome the limitation of 
current treatment such as stem cell and gene therapy. 
This study suggested the verification of therapeutic effects via MSCs-based IGF-1 gene 
therapy using FACS sorting system in myocardial infarction animal models. Especially, 
the therapeutic effects of BM-MSCs transplantation were demonstrated that cardiac 
function, capillary density and ventricular remodeling are significantly increased in 
MSCs treatment models compared with controls [12,23]. However, some problems such 
as poor cell transplantation and low viability still remain. Many studies have been 
researched to enhance therapeutic effects of MSCs cell therapy or MSCs-based gene 
therapy [12,13].
The viral vector system was known as high transfection efficiency compared to non-
viral carrier. However, the viral vector systems do not recommend for clinical trials 
because of safety aspects [14,15,16]. Normally, primary culture cells including BM-
MSCs have poor transfection efficiency when using non-viral carrier. The disadvantage of 
non-viral carrier methods is relatively low transfection efficiency, approximately 5 to 
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25% [13,14,24]. Nevertheless, the non-viral carrier is proposed an efficient delivery 
system due to their characteristics as follow; safety, stability, easy manufacturing and low 
immunogenicity [15,16]. 
To overcome the low transfection efficiency of non-viral carrier in MSCs-based gene 
therapy, new method was developed to maximize therapeutic effects of transfected gene 
via FACS analysis. In this experiment, the pEF1/His C::IGF-1::EGFP selection vector 
was constructed by inserting IGF-1 as a gene of interest and EGFP as a selective marker. 
This selection vector expressing dual gene (IGF-1 and EGFP) simultaneously was 
constructed by two steps (Figure 1, 2). First step is rat IGF-1 cDNA into pEF1/His C 
vector (pEF1/His C::IGF-1) and second step is EGFP and CMV promoter in pEGFP-C1 
into pEF1/His C::IGF-1 (pEF1/His C::IGF-1::EGFP). The pEF1/His C plasmid vector 
was selected for selection vector expressing dual gene because human EF1 alpha 
promoter of pEF1/His C plasmid vector has a high expression activity of target gene in 
stem cell line [25,26]. GFP is a convenient reporter gene for observation of transfection 
efficiency in mammalian cells because of easy detection in fluorescence microscopy and 
emits a strong green fluorescence when cells are exposed by blue light or ultraviolet (UV) 
[27,28]. Zhang et al. constructed the enhanced GFP (EGFP) vector, which makes the 
protein 35 times brighter than GFP. So, EGFP was used to visualize transfected MSCs for 
cell sorting system [28].
Furthermore, we manipulated dual genes with dual promoters in one vector to avoid 
make a fusion protein. In other words, we cloned that each gene has own promoters in 
one plasmid vector; EGFP gene with CMV promoter, IGF-1 gene with human EF1 alpha 
promoter. To confirm the regulation of rat IGF-1 gene expression by human EF1 alpha 
promoter and EGFP gene expression by CMV promoter, the pEF1/His C::IGF-1::EGFP 
vector and the non-viral vector PAM-ABP were transfected into BM-MSCs. PAM-ABP 
(ABP-conjugated PAMAM dendrimer) is a bio-reducible dendrimer-type polymer as a 
non-viral transfection reagent. It is an efficient gene delivery carrier due to their high 
transfection efficiency and low cytotoxicity compared to other reducible polymers [29].
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According to Won et al, PAM-ABP at weight ratio 5 for in vivo study provided the 
suitable balance in high level of transfection efficiency and minimal toxicity [30]. So, we 
applied weight ratio 5 of plasmid and non-viral carrier PAM-ABP for transfection of 
MSCs. 
Expression of EGFP is evaluated through fluorescence microscopy. In these results, the 
pEF1/His C::IGF-1::EGFP was dose-dependently visualized in green fluorescence and 
maximized at 8 μg dose in fluorescence microscopy (Figure 5). In RT-PCR and ELISA, 
the expression of IGF-1 was maximized at 8 μg dose (Figure 6). Therefore, the 
concentration of transfection by pEF1/His C::IGF-1::EGFP was determined at 8 μg dose 
in BM-MSCs. 
Before sorting of transfected MSCs, the transfection efficiency was approximately 20%. 
Therefore, IGF-1 expressed MSCs was one-fifth of the total in transfected MSCs by 
pEF1/His C::IGF-1::EGFP (Figure 7). After sorting, the purity of transfected-MSCs was 
approximately 95.1% through FACS selection. As a result, the purity of MSC expressed 
IGF-1 and EGFP is increased from 20% to 95.1%. (Figure 7) It implies that almost all 
MSCs express EGFP and IGF-1. 
To investigate the therapeutic effects by sorted pEF1/His C::IGF-1::EGFP-MSCs, rat 
MI groups were divided into 4 groups; PBS, control MSCs, unsorting MSCs and sorting 
MSCs. The green fluorescence as transfected MSCs was visualized in myocardium of 
ischemic left ventricle and observed in both unsorting and sorting groups. Interestingly, 
the IGF-1 transfected MSCs were significantly localized in sorting group compared to 
unsorting group (Figure 9). Also, the IGF-1 expression was increased in sorting groups 
(Figure 10). Therefore, the new therapeutic strategy by sorting system significantly 
improves the efficiency of MSCs-based gene therapy.
The TTC staining and the trichrome staining were proceeded to evaluate the 
therapeutic effects of dual gene system with FACS through histological assessment. As a 
result, infarct size and fibrosis were relatively decreased in sorting group compared to 
other groups (Figure 11). The increased IGF-1 expression by sorting system probably 
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induces the therapeutic effects as protection of fibrosis.
According to prior reports, IGF-1 is secreted by almost all tissues and plays an important 
role in cell growth, differentiation, and transformation [18,19]. Particularly, IGF-1 in the 
heart has substantially beneficial effects on cardiomyocyte function including 
proliferation and survival [18]. Raffay et al. demonstrated that exogenous administration 
of IGF-1 results in cardioprotective effects mediated through Akt pathway, pro-survival 
signaling [31]. Furthermore, survival and engraftment of MSCs are increased, and 
attenuated cardiac dysfunction, decreased myocardium apoptosis after transplantation of 
MSCs treated IGF-1 [32]. 
The present study demonstrated that the IGF-1 expression can protect the fibrosis of 
myocardium and induce decreased infarct size in MI animal models. Furthermore, the 
new therapeutic strategy by sorting system significantly improves the efficiency of 
MSCs-based gene therapy.
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V. CONCLUSION
The present study demonstrated the therapeutic effects of MSCs-based IGF-1/EGFP 
dual gene by sorting system in myocardial infarction. The IGF-1 is probably an effective 
treatment for MI. Furthermore, the MSCs-based gene therapy by sorting system would be 
a new strategy for cardiovascular disease. Promising further study will prove our 
hypothesis and reveal biological role for diverse diseases.
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ABSTRACT (In Korean)
인슐린 유사 성장인자와 녹색 형광 단백질로
유전자 변형된 중간엽 줄기세포와 선별 시스템을 이용한
랫드 심근 경색 모델의 치료효과 확인
<지도 교수 최동훈>
연세대학교 대학원 노화과학과
정수빈
심근경색은 대표적인 심혈관 질환으로 관상동맥 폐쇄가 일정시간 동안 지
속되어 심근세포가 괴사되는 상태로, 가장 전형적인 증상은 흉통이며, 호흡곤
란, 발한, 구역, 피로감, 실신 같은 비전형적인 증상이 나타난다. 손상된 심장
의 재생을 위하여 다양한 줄기세포 치료법이 제시되고 있으나, 임상적 안전성
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측면에서 중간엽 줄기세포가 가장 대표적인 세포치료법으로 제안되고 있다. 
최근, 중간엽 줄기세포의 치료 효과를 증진시키기 위하여 질환 특이적 유전자
를 도입한 세포치료법이 활발히 연구되고 있으나, 낮은 유전자 도입 효율 등
의 한계가 해결 되어야 할 문제점으로 알려져 있다. 
본 연구에서는 기존의 세포 기반 유전자 치료의 효과를 향상시키기 위하
여 두 가지 유전자를 동시에 발현하는 유전자 벡터와 선별 시스템을 이용하는
단순하면서도 효율적인 방법을 이용하였고, 랫드 심근경색 동물모델에서 그
치료 효과를 확인하였다. 
pEF1/His C 벡터에 질환 특이적 유전자인 인슐린 유사 성장인자 (Insulin-
like growth factor, IGF-1)를 삽입하였고, 선별 마커로써 녹색 형광 단백질
(enhanced green fluorescent protein, EGFP) 유전자를 복제하여 유전자 벡터를 제
작하였다. 유전자 벡터 (pEF1/His C::IGF-1::EGFP)를 중간엽 줄기세포에 유전자
도입하였을 때, 두 가지 유전자 모두 균일하게 발현하는 것을 확인하였다. 유
전자 도입 효율을 극대화 시키기 위해 형광이용세포분류기 (FACS)를 이용하
여 타겟 유전자를 발현하는 중간엽 줄기세포를 선별하였고 그 효율은 95.1%
로 확인되었다. 
심근경색 특이적 유전자 발현 중간엽 줄기세포의 치료효과를 검증하기 위
하여 랫드 심근경색 동물모델을 대조군 (PBS), 줄기세포군 (control MSCs), 비
선별 인슐린 유전자 도입 줄기세포군 (unsorting MSCs), 선별 인슐린 유전자 도
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입 줄기세포군 (sorting MSCs)으로 분류하였다. 세포 주입 2주 후 실험동물을
희생시켜 심장조직을 면역 형광 염색, TTC 염색, Masson’s trichrome 염색을 통
하여 치료효과를 확인하였다. 
선별 인슐린 유전자 줄기세포 군에서 녹색 형광 발현 세포와 인슐린 발현
세포가 현저히 많이 관찰되었다. TTC 염색의 경우에도 선별 인슐린 유전자 줄
기세포 군에서 심근경색의 크기가 감소하였고 (PBS 31.50%, control MSCs 
12.61%, unsorting 10.42%, sorting 5.74%), 심근섬유화가 현저히 감소된 것을 확인
하였다. 
그러므로, 인슐린 유사 성장인자는 허혈성 심장의 경색과 섬유화를 억제하
는 것을 확인할 수 있었다. 또한, 두 가지 유전자를 발현하는 유전자 벡터와
선별 시스템은 유전자 도입 효율을 높임으로써 인슐린 유사 성장인자의 심근
경색의 치료효과를 극대화하였다. 더 나아가, 질환 특이적 유전자 도입 세포
선별방식은 심근경색뿐만 아니라 다양한 질병들에 적용할 수 있을 것으로 기
대된다.
핵심 되는 말: 인슐린 유사 성장인자, 특이적 플라스미드 벡터, 선별 시스템, 
듀얼 프로모터, 도입된 유전자 효과, 심근 경색
